Anifrolumab Malignancy and Serious Infections Study

Sponsor
AstraZeneca
Study ID
NCT07000110
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 130 Years
Healthy Volunteers
Not accepted

Interventions

  • Anifrolumab — DRUG
    Anifrolumab prescribed per local practice

Study Details

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.

Key Dates

First listed
Jun 2, 2025
Start date
Jan 26, 2026
Status verified
Jun 2026
Primary completion
Nov 30, 2031
Completion
Nov 30, 2031

Study Design

Enrollment
3,195 participants (estimated)

Primary Outcome Measure

Malignancies [ Time Frame: Indexdate to November 2031 ]

Central Contacts

Find similar trials

Nationwide
Lupus (SLE) trialsRheumatology trialsAutoimmune disease trials

Related Studies